CIBC World Keeps 'Buy' on Andrx Group
Andrx Group (ADRX ) gained after CIBC World says it views the recent weakness as a buying opportunity.
Analyst Elliot Wilbur says no incremental information has emerged to cause him to alter his expectations for timeline of or ultimate economic potential for near-term product launches. He notes this includes Tiazac for hypertension, Wellbutrin SR for depression, and Prilosec for gastroesophageal reflux disease.
He thinks ADRX will achieve his $1.99 2002 EPS estimate (excluding Prilosec), and an 20% average EPS growth through 2005. He reiterated buy rating on the stock, but given the current market conditions, he cut his $105 price target to $44.